Bridgebio Oncology Therapeutics Inc (BBOT)

$11.51 -1.16 (-9.16%)
Market Cap 1.01B
Revenue (ttm) 0.00
Net Income (ttm) -74.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 710,200
Avg Vol 230,728
Day's Range N/A - N/A
Shares Out 79.99M
Stochastic %K 25%
Beta 0.12
Analysts Strong Sell
Price Target $24.14

Company Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide 3-kinase malignancies. The company's product pipeline includes BBO-8520, a direct inhibitor targeting the on and off states of KRAS that is in Phase I clinical trial to treat patients with KRASG12C mutant non-small cell lung cancer; and BBO-10203, an orally bioavailable small molecule that is in Phase I cl...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 405 4770
Website: bbotx.com
Address:
256 E. Grand Avenue, Suite 104, South San Francisco, United States
Quantumup
Quantumup Jan. 12 at 3:25 PM
Truist reiterated $RVMD Buy-$99 and said: $28-$32 Billion Is Closer To What We Think RVMD Would Find Appealing $MRK $BBOT $ERAS AMGN BMY $IMTX Truist added: We think RVMD remains in a position of strength, and doesn't need to do a deal. If RVMD is getting bought out in the near term, we think it would be for an offer that was difficult to refuse, and we think the range suggested in the Financial Times article ($28-$32 billion) is more in the vicinity of that number. A bid from Merck (MRK, NR) could make sense, in our view, providing antitrust conditions are met (see below). But at this price range, we think a potential acquirer would want to see some Phase 3 data to de-risk Daraxon - either topline data from RASolute-302 (potentially due in 1H26, we think), or perhaps an interim look at this same study (which we think could have happened, or will happen soon).
0 · Reply
Quantumup
Quantumup Jan. 9 at 1:02 PM
Raymond James🏁 $BBOT $RVMD MRK $BBIO spinout RJ: We are initiating coverage of BridgeBio Oncology (BBOT) with an Outperform rating and a price target price of $24. Our rating is based on four points: 1) We see the preliminary activity and safety profile of BBO-8520, a KRAS G12C selective inhibitor, observed in a Phase 1 NSCLC trial as promising. BBO-8520 is poised to become a new contender in the 1L NSCLC setting with pembrolizumab combination data as well. 2) The company's pan-KRAS inhibitor, BBO-11818, has a broad and potent inhibitory activity while avoiding NRAS/HRAS inhibition with early signals of dose response. 3) We view the RAS:PI3Ka breaker, BBO-10203, as a unique angle to break into metastatic breast cancer that can potentially evolve into a differentiated drug class pending initial Phase 1 combination results in 2H 2026. 4) The company is well capitalized to get through proof of concept updates for all assets. Our confidence is tempered by crowding in the KRAS inhibitor field.
0 · Reply
Quantumup
Quantumup Jan. 8 at 5:41 PM
BofA⬆️Top Pick $RVMD's PT to $109 from $98, reiterated at Buy, +⬆️dara's PoS in 1L PDAC to 65% from 60%, in NSCLC from 40% to 50% in 1L &⬆️zoldonrasib's PoS in 1L to 55% from 45% & 2L PDAC to 50% from 40% & to 50% from 40% in 2L+ NSCLC after the Tx received BTD in this setting $BBOT $ERAS $IMRX $AMGN BMY Here's what BofA had to say in its note to investors:
0 · Reply
Quantumup
Quantumup Jan. 8 at 1:22 PM
Stifel y'day reiterated $RVMD Buy-$85, w/ PT under review. $BBOT $ERAS $IMRX BMY $AMGN Stifel said~News regarding ABBV being in advanced talks to acquire RVMD was circulating this afternoon - this news was later refuted by ABBV, but we have gotten a lot of questions on what take out valuation could make sense for RVMD. We were surprised by the timing of this speculation, given that RVMD management has recently given the impression that they intend to remain independent near term. However, if it were to be acquired at this stage, we think RVMD could easily go in the $30B+ range. Our target price and rating are currently under review as we further evaluate impact of this RVMD M&A speculation; our current target price does not factor in an M&A premium.
1 · Reply
TheBullishTrade
TheBullishTrade Jan. 7 at 8:01 PM
$BBOT BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs Wednesday, 7th January at 7:00 am BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response. BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pembrolizumab monotherapy. BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation. BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels; combination studies with standard-of-care (SOC) treatments in colorectal cancer (CRC) and breast cancer (BC) have been initiated; internal combination studies with BBO-8520 and BBO-11818 are anticipated to open this year. Company webcast to be held today at 8:30 a.m. Eastern Time (ET).
0 · Reply
prismmarketview
prismmarketview Jan. 7 at 6:13 PM
$BBOT ’s ON/OFF Biology: A Game-Changer in Oncology https://prismmarketview.com/bbots-on-off-biology-a-game-changer-in-oncology/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 3:58 PM
$BBOT Current Stock Price: $12.59
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 12:25 AM
$BBOT Current Stock Price: $12.31
0 · Reply
BundleBaron
BundleBaron Dec. 26 at 9:14 AM
$BBOT Macro trends are relevant, yet internal execution remains the decisive catalyst. Margins must remain resilient as activity scales. Visible traction across indicators would support the story. Without confirmation, volatility likely persists.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 8:32 PM
$BBOT Current Stock Price: $12.19
0 · Reply
Latest News on BBOT
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jan 13, 2026, 4:05 PM EST - 12 hours ago

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

Jan 13, 2026, 12:16 PM EST - 16 hours ago

BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

Jan 7, 2026, 7:00 AM EST - 6 days ago

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 4:05 PM EST - 4 weeks ago

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least

Dec 12, 2025, 5:32 PM EST - 4 weeks ago

BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 11, 2025, 4:05 PM EST - 4 weeks ago

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

Dec 10, 2025, 4:05 PM EST - 4 weeks ago

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

BBOT to Participate in Upcoming December Investor Healthcare Conferences

Nov 18, 2025, 4:05 PM EST - 2 months ago

BBOT to Participate in Upcoming December Investor Healthcare Conferences

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Nov 12, 2025, 4:05 PM EST - 2 months ago

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

HLXB

BBOT to Participate in the Jefferies Global Healthcare Conference in London

Nov 3, 2025, 4:05 PM EST - 2 months ago

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Oct 30, 2025, 5:45 PM EDT - 2 months ago

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

Oct 25, 2025, 12:30 PM EDT - 2 months ago

Preclinical Data Presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Support Potential of BBO-10203, a First-in-Class RAS:PI3Kα Breaker That Inhibits KRAS-Mutant Tumor Growth without Inducing Hyperglycemia

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 4:05 PM EDT - 2 months ago

BBOT Presents Preclinical Data Demonstrating Potential of BBO-11818 as a Potent panKRAS Inhibitor at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 13, 2025, 4:05 PM EDT - 3 months ago

BBOT Announces Poster Presentations at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BBOT to Participate in Upcoming September Investor Healthcare Conferences

Aug 20, 2025, 8:00 AM EDT - 5 months ago

BBOT to Participate in Upcoming September Investor Healthcare Conferences

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

Aug 11, 2025, 4:30 PM EDT - 5 months ago

BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition

HLXB

Quantumup
Quantumup Jan. 12 at 3:25 PM
Truist reiterated $RVMD Buy-$99 and said: $28-$32 Billion Is Closer To What We Think RVMD Would Find Appealing $MRK $BBOT $ERAS AMGN BMY $IMTX Truist added: We think RVMD remains in a position of strength, and doesn't need to do a deal. If RVMD is getting bought out in the near term, we think it would be for an offer that was difficult to refuse, and we think the range suggested in the Financial Times article ($28-$32 billion) is more in the vicinity of that number. A bid from Merck (MRK, NR) could make sense, in our view, providing antitrust conditions are met (see below). But at this price range, we think a potential acquirer would want to see some Phase 3 data to de-risk Daraxon - either topline data from RASolute-302 (potentially due in 1H26, we think), or perhaps an interim look at this same study (which we think could have happened, or will happen soon).
0 · Reply
Quantumup
Quantumup Jan. 9 at 1:02 PM
Raymond James🏁 $BBOT $RVMD MRK $BBIO spinout RJ: We are initiating coverage of BridgeBio Oncology (BBOT) with an Outperform rating and a price target price of $24. Our rating is based on four points: 1) We see the preliminary activity and safety profile of BBO-8520, a KRAS G12C selective inhibitor, observed in a Phase 1 NSCLC trial as promising. BBO-8520 is poised to become a new contender in the 1L NSCLC setting with pembrolizumab combination data as well. 2) The company's pan-KRAS inhibitor, BBO-11818, has a broad and potent inhibitory activity while avoiding NRAS/HRAS inhibition with early signals of dose response. 3) We view the RAS:PI3Ka breaker, BBO-10203, as a unique angle to break into metastatic breast cancer that can potentially evolve into a differentiated drug class pending initial Phase 1 combination results in 2H 2026. 4) The company is well capitalized to get through proof of concept updates for all assets. Our confidence is tempered by crowding in the KRAS inhibitor field.
0 · Reply
Quantumup
Quantumup Jan. 8 at 5:41 PM
BofA⬆️Top Pick $RVMD's PT to $109 from $98, reiterated at Buy, +⬆️dara's PoS in 1L PDAC to 65% from 60%, in NSCLC from 40% to 50% in 1L &⬆️zoldonrasib's PoS in 1L to 55% from 45% & 2L PDAC to 50% from 40% & to 50% from 40% in 2L+ NSCLC after the Tx received BTD in this setting $BBOT $ERAS $IMRX $AMGN BMY Here's what BofA had to say in its note to investors:
0 · Reply
Quantumup
Quantumup Jan. 8 at 1:22 PM
Stifel y'day reiterated $RVMD Buy-$85, w/ PT under review. $BBOT $ERAS $IMRX BMY $AMGN Stifel said~News regarding ABBV being in advanced talks to acquire RVMD was circulating this afternoon - this news was later refuted by ABBV, but we have gotten a lot of questions on what take out valuation could make sense for RVMD. We were surprised by the timing of this speculation, given that RVMD management has recently given the impression that they intend to remain independent near term. However, if it were to be acquired at this stage, we think RVMD could easily go in the $30B+ range. Our target price and rating are currently under review as we further evaluate impact of this RVMD M&A speculation; our current target price does not factor in an M&A premium.
1 · Reply
TheBullishTrade
TheBullishTrade Jan. 7 at 8:01 PM
$BBOT BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs Wednesday, 7th January at 7:00 am BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response. BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pembrolizumab monotherapy. BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escalation. BBO-10203 demonstrated a potentially differentiated safety profile without any observed events of hyperglycemia and without any enrollment restrictions on baseline HbA1c and glucose levels; combination studies with standard-of-care (SOC) treatments in colorectal cancer (CRC) and breast cancer (BC) have been initiated; internal combination studies with BBO-8520 and BBO-11818 are anticipated to open this year. Company webcast to be held today at 8:30 a.m. Eastern Time (ET).
0 · Reply
prismmarketview
prismmarketview Jan. 7 at 6:13 PM
$BBOT ’s ON/OFF Biology: A Game-Changer in Oncology https://prismmarketview.com/bbots-on-off-biology-a-game-changer-in-oncology/
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 3:58 PM
$BBOT Current Stock Price: $12.59
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 31 at 12:25 AM
$BBOT Current Stock Price: $12.31
0 · Reply
BundleBaron
BundleBaron Dec. 26 at 9:14 AM
$BBOT Macro trends are relevant, yet internal execution remains the decisive catalyst. Margins must remain resilient as activity scales. Visible traction across indicators would support the story. Without confirmation, volatility likely persists.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 25 at 8:32 PM
$BBOT Current Stock Price: $12.19
0 · Reply
SustainableStoxV2
SustainableStoxV2 Dec. 25 at 11:14 AM
$BBOT Expectations are shifting from future promises toward demonstrated capability. Resource allocation will signal whether leadership prioritizes endurance or speed. Successful iteration can create optionality that is not yet fully priced. Future re‑rating depends on tightening the gap between narrative and reality.
0 · Reply
RunnerSignals
RunnerSignals Dec. 12 at 8:42 PM
Stock Upgrades Today Show Top Picks $GCTS $IBRX $XOMA $BBOT $VG Ultra-high-octane crew today. Feels like the market found a hidden cheat code for upside https://stocksrunner.com/news/2025-12-12-stock-upgrades-today-show-top-picks
0 · Reply
prismmarketview
prismmarketview Dec. 11 at 3:22 PM
BridgeBio Oncology Therapeutics (Nasdaq: $BBOT) unveils new preclinical data showing its first-in-class RAS:PI3Kα breaker BBO-10203 delivers strong anti-tumor activity without hyperglycemia—one of the biggest limitations of PI3K inhibitors. Phase 1 BREAKER-101 is underway with initial data expected in 1H 2026. https://prismmarketview.com/bbot-unveils-promising-preclinical-data-for-first-in-class-raspi3k%ce%b1-breaker-bbo-10203-at-sabcs-2025/
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:29 PM
Wedbush has adjusted their stance on BridgeBio Oncology ( $BBOT ), setting the rating to Outperform with a target price of 25.
0 · Reply
Irish_lass
Irish_lass Dec. 10 at 9:30 PM
$BBOT https://investors.bbotx.com/news-releases/news-release-details/bbot-announces-late-breaking-preclinical-data-bbo-10203-first
0 · Reply
mbruland
mbruland Dec. 6 at 1:23 PM
$BBOT I started watching BBIO at around $30. The company had a really good reputation. I didn't buy and now it's mid 70's. Happy for those who bought early. Thinking now about BBOT, SNDX, CRNX, and VKTX.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Dec. 6 at 11:52 AM
$BBIO $BBOT my exposure has been via BBIO. Not a bad idea to start building a position soon.
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 3:22 PM
Morgan Stanley has adjusted their stance on BridgeBio Oncology ( $BBOT ), setting the rating to Overweight with a target price of 20.
0 · Reply
Quantumup
Quantumup Dec. 5 at 1:17 PM
Morgan Stanley🏁 $BBOT Overweight/$20 $BBIO $RVMD Here's what Morgan Stanley had to say: https://x.com/Quantumup1/status/1996931177412804795?s=20
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 3 at 5:56 PM
$BBOT
0 · Reply
topstockalerts
topstockalerts Dec. 1 at 1:01 PM
Pre Market Top Gainers PT2 $BBOT $KALA $DLPN $BLTE $AACG
0 · Reply
RunnerSignals
RunnerSignals Nov. 26 at 9:44 PM
$AVB $AVBP $AXS $BAER $BBOT showing massive upside! and these tickers aren’t shy https://stocksrunner.com/news/2025-11-26-stock-upgrades-today-see-wall-street-boost-confidence
0 · Reply